NCT03714126 is a clinical trial of Cordio Medical in Heart Failure, sponsored by Cordio Medical.

Who is sponsoring NCT03714126?

NCT03714126 is sponsored by Cordio Medical.

What drugs are being tested in NCT03714126?

Interventions in NCT03714126: Cordio Medical.

What condition does NCT03714126 study?

NCT03714126 studies Heart Failure.

Is NCT03714126 still recruiting?

NCT03714126 is currently completed. Last updated 9 March 2021.

Last reviewed 2021-03-09 · How we verify

NCT03714126

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remote Speech Analysis in HF Patients Undergoing Haemodialysis

Completed Last updated 9 March 2021

What this trial tests

trial testing Cordio Medical in Heart Failure in 6 participants. Completed in 8 March 2021.

Timeline

27 March 2019

Primary endpoint
8 March 2021

8 March 2021

Quick facts

Lead sponsor	Cordio Medical
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6
Start date	27 March 2019
Primary completion	8 March 2021
Estimated completion	8 March 2021
Sites	1 location across Israel

Drugs / interventions tested

Cordio Medical

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Cordio Medical

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, non-interventional, prospective, single-arm, open study for database establishment for R\&D purposes. The study will be conducted in 1 site in Israel with up to fifty (50) patients. Patients under hemodialysis supervision will be enrolled in the clinical trial. Clinical information for the study will be collected at the hospital and at home. The patient will conduct recordings at home every day.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Cordio Medical trials

Trials by the same sponsor.

NCT05876533 — R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances · active not recruiting
NCT06378632 — AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM · recruiting
NCT04325048 — Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03714126 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cordio Medical
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03714126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing